Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
Identifieur interne : 000516 ( Main/Exploration ); précédent : 000515; suivant : 000517Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
Auteurs : P. Wutzler [Allemagne] ; K-D Kossow ; H. Lode ; B R Ruf ; H. Scholz ; G E VogelSource :
- Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [ 1386-6532 ] ; 2004.
Descripteurs français
- KwdFr :
- Acides sialiques (usage thérapeutique), Acétamides (usage thérapeutique), Allemagne, Amantadine (usage thérapeutique), Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Grippe humaine (), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Guanidines, Humains, Oséltamivir, Pyrannes, Résistance virale aux médicaments, Soins de santé primaires, Virus de la grippe A (), Virus influenza B (), Zanamivir.
- MESH :
- administration et posologie : Antiviraux.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Acides sialiques, Acétamides, Amantadine, Antiviraux.
- virologie : Grippe humaine.
- Allemagne, Grippe humaine, Guanidines, Humains, Oséltamivir, Pyrannes, Résistance virale aux médicaments, Soins de santé primaires, Virus de la grippe A, Virus influenza B, Zanamivir.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Acetamides (therapeutic use), Amantadine (therapeutic use), Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Drug Resistance, Viral, Germany, Guanidines, Humans, Influenza A virus (drug effects), Influenza B virus (drug effects), Influenza, Human (drug therapy), Influenza, Human (prevention & control), Influenza, Human (virology), Oseltamivir, Primary Health Care, Pyrans, Sialic Acids (therapeutic use), Zanamivir.
- MESH :
- chemical , administration & dosage : Antiviral Agents.
- chemical , therapeutic use : Acetamides, Amantadine, Antiviral Agents, Sialic Acids.
- geographic : Germany, Guanidines, Oseltamivir, Pyrans, Zanamivir.
- drug effects : Influenza A virus, Influenza B virus.
- drug therapy : Influenza, Human.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Drug Resistance, Viral, Humans, Primary Health Care.
Abstract
Antiviral drugs are a valuable supplementation to vaccines for the control and prevention of influenza. In Germany, for treating influenza amantadine, oseltamivir and zanamivir are approved. Amantadine and oseltamivir are also licensed for prophylactic use. On behalf of the Paul-Ehrlich-Society of Germany and the German Association for the Control of Virus Diseases, as two independent scientific societies, the first consensus Conference on the Antiviral Treatment and Prophylaxis of Influenza was held in June 2002. Based on the available data of clinical studies an expert group developed the following recommendations for the appropriate clinical use of the antiviral drugs: (1) since oseltamivir (orally administered) and zanamivir (administered by inhalation) have apparently similar clinical efficacy both drugs can be used alternatively for treatment. (2) Amantadine is not an alternative to the neuraminidase (NA) inhibitors because it is not effective against influenza B viruses, it frequently selects resistant virus mutants and it can cause adverse events. (3) When influenza is prevalent in the community patients with the clinical diagnosis of influenza should be treated with neuraminidase inhibitors if the symptoms are lasting not longer than 48 h. (4) Immunocompetent patients with a non-febrile illness and patients with a symptom history of more than 2 days should not be treated with antiviral drugs. (5) Although there are no data from clinical trials immunocompromised patients should also be treated when influenza has been diagnosed. (6) The prophylactic use of antiviral drugs can be recommended for persons with close contact to acutely ill persons and no recent vaccination against influenza. (7) The use of anti-influenza drugs have to be considered for prophylaxis in pandemics. A precondition for the adequate use of anti-influenza drugs in the primary medical care is the timely information on the local influenza situation delivered by surveillance systems.
DOI: 10.1016/j.jcv.2004.05.009
PubMed: 15364262
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.</title><author><name sortKey="Wutzler, P" sort="Wutzler, P" uniqKey="Wutzler P" first="P" last="Wutzler">P. Wutzler</name><affiliation wicri:level="1"><nlm:affiliation>Institut für Virologie und Antivirale Therapie, Klinikum der Friedrich-Schiller Universität, Hans-Knöll-Strasse 2, D-07745 Jena, Germany. peter.wutzler@med.uni-jena.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institut für Virologie und Antivirale Therapie, Klinikum der Friedrich-Schiller Universität, Hans-Knöll-Strasse 2, D-07745 Jena</wicri:regionArea><wicri:noRegion>07745 Jena</wicri:noRegion><wicri:noRegion>07745 Jena</wicri:noRegion><wicri:noRegion>D-07745 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Kossow, K D" sort="Kossow, K D" uniqKey="Kossow K" first="K-D" last="Kossow">K-D Kossow</name></author><author><name sortKey="Lode, H" sort="Lode, H" uniqKey="Lode H" first="H" last="Lode">H. Lode</name></author><author><name sortKey="Ruf, B R" sort="Ruf, B R" uniqKey="Ruf B" first="B R" last="Ruf">B R Ruf</name></author><author><name sortKey="Scholz, H" sort="Scholz, H" uniqKey="Scholz H" first="H" last="Scholz">H. Scholz</name></author><author><name sortKey="Vogel, G E" sort="Vogel, G E" uniqKey="Vogel G" first="G E" last="Vogel">G E Vogel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15364262</idno><idno type="pmid">15364262</idno><idno type="doi">10.1016/j.jcv.2004.05.009</idno><idno type="wicri:Area/Main/Corpus">000526</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000526</idno><idno type="wicri:Area/Main/Curation">000526</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000526</idno><idno type="wicri:Area/Main/Exploration">000526</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.</title><author><name sortKey="Wutzler, P" sort="Wutzler, P" uniqKey="Wutzler P" first="P" last="Wutzler">P. Wutzler</name><affiliation wicri:level="1"><nlm:affiliation>Institut für Virologie und Antivirale Therapie, Klinikum der Friedrich-Schiller Universität, Hans-Knöll-Strasse 2, D-07745 Jena, Germany. peter.wutzler@med.uni-jena.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institut für Virologie und Antivirale Therapie, Klinikum der Friedrich-Schiller Universität, Hans-Knöll-Strasse 2, D-07745 Jena</wicri:regionArea><wicri:noRegion>07745 Jena</wicri:noRegion><wicri:noRegion>07745 Jena</wicri:noRegion><wicri:noRegion>D-07745 Jena</wicri:noRegion></affiliation></author><author><name sortKey="Kossow, K D" sort="Kossow, K D" uniqKey="Kossow K" first="K-D" last="Kossow">K-D Kossow</name></author><author><name sortKey="Lode, H" sort="Lode, H" uniqKey="Lode H" first="H" last="Lode">H. Lode</name></author><author><name sortKey="Ruf, B R" sort="Ruf, B R" uniqKey="Ruf B" first="B R" last="Ruf">B R Ruf</name></author><author><name sortKey="Scholz, H" sort="Scholz, H" uniqKey="Scholz H" first="H" last="Scholz">H. Scholz</name></author><author><name sortKey="Vogel, G E" sort="Vogel, G E" uniqKey="Vogel G" first="G E" last="Vogel">G E Vogel</name></author></analytic><series><title level="j">Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</title><idno type="ISSN">1386-6532</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (therapeutic use)</term><term>Amantadine (therapeutic use)</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (therapeutic use)</term><term>Drug Resistance, Viral</term><term>Germany</term><term>Guanidines</term><term>Humans</term><term>Influenza A virus (drug effects)</term><term>Influenza B virus (drug effects)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Oseltamivir</term><term>Primary Health Care</term><term>Pyrans</term><term>Sialic Acids (therapeutic use)</term><term>Zanamivir</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acides sialiques (usage thérapeutique)</term><term>Acétamides (usage thérapeutique)</term><term>Allemagne</term><term>Amantadine (usage thérapeutique)</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Grippe humaine ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Guanidines</term><term>Humains</term><term>Oséltamivir</term><term>Pyrannes</term><term>Résistance virale aux médicaments</term><term>Soins de santé primaires</term><term>Virus de la grippe A ()</term><term>Virus influenza B ()</term><term>Zanamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term><term>Amantadine</term><term>Antiviral Agents</term><term>Sialic Acids</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term><term>Guanidines</term><term>Oseltamivir</term><term>Pyrans</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acides sialiques</term><term>Acétamides</term><term>Amantadine</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance, Viral</term><term>Humans</term><term>Primary Health Care</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Allemagne</term><term>Grippe humaine</term><term>Guanidines</term><term>Humains</term><term>Oséltamivir</term><term>Pyrannes</term><term>Résistance virale aux médicaments</term><term>Soins de santé primaires</term><term>Virus de la grippe A</term><term>Virus influenza B</term><term>Zanamivir</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antiviral drugs are a valuable supplementation to vaccines for the control and prevention of influenza. In Germany, for treating influenza amantadine, oseltamivir and zanamivir are approved. Amantadine and oseltamivir are also licensed for prophylactic use. On behalf of the Paul-Ehrlich-Society of Germany and the German Association for the Control of Virus Diseases, as two independent scientific societies, the first consensus Conference on the Antiviral Treatment and Prophylaxis of Influenza was held in June 2002. Based on the available data of clinical studies an expert group developed the following recommendations for the appropriate clinical use of the antiviral drugs: (1) since oseltamivir (orally administered) and zanamivir (administered by inhalation) have apparently similar clinical efficacy both drugs can be used alternatively for treatment. (2) Amantadine is not an alternative to the neuraminidase (NA) inhibitors because it is not effective against influenza B viruses, it frequently selects resistant virus mutants and it can cause adverse events. (3) When influenza is prevalent in the community patients with the clinical diagnosis of influenza should be treated with neuraminidase inhibitors if the symptoms are lasting not longer than 48 h. (4) Immunocompetent patients with a non-febrile illness and patients with a symptom history of more than 2 days should not be treated with antiviral drugs. (5) Although there are no data from clinical trials immunocompromised patients should also be treated when influenza has been diagnosed. (6) The prophylactic use of antiviral drugs can be recommended for persons with close contact to acutely ill persons and no recent vaccination against influenza. (7) The use of anti-influenza drugs have to be considered for prophylaxis in pandemics. A precondition for the adequate use of anti-influenza drugs in the primary medical care is the timely information on the local influenza situation delivered by surveillance systems.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15364262</PMID><DateCompleted><Year>2004</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1386-6532</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title><ISOAbbreviation>J. Clin. Virol.</ISOAbbreviation></Journal><ArticleTitle>Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.</ArticleTitle><Pagination><MedlinePgn>84-91</MedlinePgn></Pagination><Abstract><AbstractText>Antiviral drugs are a valuable supplementation to vaccines for the control and prevention of influenza. In Germany, for treating influenza amantadine, oseltamivir and zanamivir are approved. Amantadine and oseltamivir are also licensed for prophylactic use. On behalf of the Paul-Ehrlich-Society of Germany and the German Association for the Control of Virus Diseases, as two independent scientific societies, the first consensus Conference on the Antiviral Treatment and Prophylaxis of Influenza was held in June 2002. Based on the available data of clinical studies an expert group developed the following recommendations for the appropriate clinical use of the antiviral drugs: (1) since oseltamivir (orally administered) and zanamivir (administered by inhalation) have apparently similar clinical efficacy both drugs can be used alternatively for treatment. (2) Amantadine is not an alternative to the neuraminidase (NA) inhibitors because it is not effective against influenza B viruses, it frequently selects resistant virus mutants and it can cause adverse events. (3) When influenza is prevalent in the community patients with the clinical diagnosis of influenza should be treated with neuraminidase inhibitors if the symptoms are lasting not longer than 48 h. (4) Immunocompetent patients with a non-febrile illness and patients with a symptom history of more than 2 days should not be treated with antiviral drugs. (5) Although there are no data from clinical trials immunocompromised patients should also be treated when influenza has been diagnosed. (6) The prophylactic use of antiviral drugs can be recommended for persons with close contact to acutely ill persons and no recent vaccination against influenza. (7) The use of anti-influenza drugs have to be considered for prophylaxis in pandemics. A precondition for the adequate use of anti-influenza drugs in the primary medical care is the timely information on the local influenza situation delivered by surveillance systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wutzler</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut für Virologie und Antivirale Therapie, Klinikum der Friedrich-Schiller Universität, Hans-Knöll-Strasse 2, D-07745 Jena, Germany. peter.wutzler@med.uni-jena.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kossow</LastName><ForeName>K-D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Lode</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ruf</LastName><ForeName>B R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>G E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><CollectiveName>Expert Group, German Association for the Control of Virus Diseases and Paul-Ehrlich Society of Germany</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016431">Guideline</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Virol</MedlineTA><NlmUniqueID>9815671</NlmUniqueID><ISSNLinking>1386-6532</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006146">Guanidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011714">Pyrans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012794">Sialic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Virol. 2005 May;33(1):79</RefSource><PMID Version="1">15797370</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011714" MajorTopicYN="N">Pyrans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012794" MajorTopicYN="N">Sialic Acids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15364262</ArticleId><ArticleId IdType="doi">10.1016/j.jcv.2004.05.009</ArticleId><ArticleId IdType="pii">S1386653204001611</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Kossow, K D" sort="Kossow, K D" uniqKey="Kossow K" first="K-D" last="Kossow">K-D Kossow</name><name sortKey="Lode, H" sort="Lode, H" uniqKey="Lode H" first="H" last="Lode">H. Lode</name><name sortKey="Ruf, B R" sort="Ruf, B R" uniqKey="Ruf B" first="B R" last="Ruf">B R Ruf</name><name sortKey="Scholz, H" sort="Scholz, H" uniqKey="Scholz H" first="H" last="Scholz">H. Scholz</name><name sortKey="Vogel, G E" sort="Vogel, G E" uniqKey="Vogel G" first="G E" last="Vogel">G E Vogel</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Wutzler, P" sort="Wutzler, P" uniqKey="Wutzler P" first="P" last="Wutzler">P. Wutzler</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000516 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000516 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15364262
|texte= Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15364262" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |